Patents by Inventor Yate-Ching Yuan

Yate-Ching Yuan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PARG inhibitors and method of use thereof
    Patent number: 11858879
    Abstract: Provided herein are, inter alia, compounds inhibiting poly(ADP-ribose) Glycohydrolase (PARG) in a cancer cell and methods of treating cancer using compounds of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: January 2, 2024
    Assignee: CITY OF HOPE
    Inventors: Xiaochun Yu, Shih-Hsun Chen, Yate-Ching Yuan, Hongzhi Li, David Horne
  • PARG INHIBITORS AND METHOD OF USE THEREOF
    Publication number: 20220002231
    Abstract: Provided herein are, inter alia, compounds inhibiting poly(ADP-ribose) Glycohydrolase (PARG) in a cancer cell and methods of treating cancer using compounds of the invention.
    Type: Application
    Filed: June 22, 2018
    Publication date: January 6, 2022
    Inventors: Xiaochun Yu, Shih-Hsun Chen, Yate-Ching Yuan, Hongzhi LI, David Horne
  • Cell culture model for acquired chemoresistance of chronic myelogenous leukemia and related methods for identifying agents to overcome resistance
    Patent number: 9176114
    Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: November 3, 2015
    Assignee: CITY OF HOPE
    Inventors: WenYong Chen, Ravi Bhatia, Leila Su, Yate-Ching Yuan
  • Cell culture model for acquired chemoresistance of chronic myelogenous leukemia and related methods for identifying agents to overcome resistance
    Patent number: 8580488
    Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: November 12, 2013
    Assignee: City of Hope
    Inventors: WenYong Chen, Ravi Bhatia, Leila Su, Yate-Ching Yuan
  • CELL CULTURE MODEL FOR ACQUIRED CHEMORESISTANCE OF CHRONIC MYELOGENOUS LEUKEMIA AND RELATED METHODS FOR IDENTIFYING AGENTS TO OVERCOME RESISTANCE
    Publication number: 20130288367
    Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.
    Type: Application
    Filed: June 19, 2013
    Publication date: October 31, 2013
    Inventors: WenYong CHEN, Ravi BHATIA, Leila SU, Yate-Ching YUAN
  • Ribonucleotide reductase inhibitors and methods of use
    Patent number: 8163783
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: April 24, 2012
    Assignee: City of Hope
    Inventors: Yun Yen, David Horne, Yate-Ching Yuan, Bing-Sen Zhou, Angela L Perkins Harki, Leila Su
  • RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE
    Publication number: 20110245304
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Application
    Filed: April 25, 2011
    Publication date: October 6, 2011
    Inventors: Yun YEN, David Horne, Yate-Ching Yuan, Bing-Sen Zhou, Angela L. Perkins Harki, Leila Su
  • Ribonucleotide reductase inhibitors and methods of use
    Patent number: 7956076
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: June 7, 2011
    Assignee: City of Hope
    Inventors: Yun Yen, David Horne, Yate-Ching Yuan, Bing-Sen Zhou, Angela L Perkins Harki, Leila Su
  • CELL CULTURE MODEL FOR ACQUIRED CHEMORESISTANCE OF CHRONIC MYELOGENOUS LEUKEMIA AND RELATED METHODS FOR IDENTIFYING AGENTS TO OVERCOME RESISTANCE
    Publication number: 20110092695
    Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 21, 2011
    Inventors: WenYong Chen, Ravi Bhatia, Leila Su, Yate-Ching Yuan
  • RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE
    Publication number: 20090258915
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Application
    Filed: April 8, 2009
    Publication date: October 15, 2009
    Inventors: Yun Yen, David Horne, Yate-Ching Yuan